Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer

Neoplasia

Volumn 13, Issue 2, 2011, Pages 180-186

  Fendrich, Volker ^a   Schneider, Ralph ^a   Maitra, Anirban ^b   Jacobsen, Ilse D ^c   Opfermann, Thomas ^c   Bartsch, Detlef K ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HANS KNÖLL INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASPARTIC ACID; CRE RECOMBINASE; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 2 ANTIBODY; GLYCINE; HISTIDINE; K RAS PROTEIN; PROTEIN ANTIBODY; TRANSCRIPTION FACTOR PDX 1; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CARCINOMA IN SITU; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC INTRAEPITHELIAL NEOPLASIA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 79951477833     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.10956     Document Type: Article

References (22)

1. Jemal A, Siegel R, and Ward E (2006). Cancer statistics, 2006. CA Cancer J Clin 56, 106-130.
2. Feldmann G and Maitra A (2008). Molecular genetics of pancreatic ductal adenocarcinomasand recent implications for translational efforts. J Mol Diagn 10, 111-122.
3. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, Kern SE, Klimstra DS, Kloppel G, Longnecker DS, et al. (2001). Pancreaticintraepithelial neoplasia: a new nomenclature and classification system for pancreaticduct lesions. Am J Surg Pathol 25, 579-586.
4. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, et al. (2003). Preinvasive and invasiveductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450.
5. Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, Rustgi AK, Chang S, and Tuveson D (2005). Trp53R172H and Kras G12Dcooperate to promote chromosomal instability and widely metastatic pancreaticductal adenocarcinoma in mice. Cancer Cell 7, 469-483.
6. Fendrich V, Chen NM, Neef M, Waldmann J, Bucholz M, Feldmann G, Slater EP, Maitra A, and Bartsch DK (2010). The angiotensin-I-converting enzymeinhibitor enalapril and aspirin delay progression of pancreatic intraepithelialneoplasia and cancer formation in a genetically engineered mouse model of pancreaticcancer. Gut 59, 630-637.
7. Leturque A, Brot-Laroche E, and Le Gall M (2009). GLUT2 mutations, translocation, and receptor function in diet sugar managing. Am J Physiol Endocrinol Metab 296, E985-E992.
8. Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, and Song SY (2006). The clinical usefulness of 18-fluorodeoxyglucose positron emission tomographyin the differential diagnosis, staging and response evaluation after concurrentchemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40, 923-929.
9. Delbeke D and Pinson CW (2004). Pancreatic tumors: role of imaging in thediagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 11, 4-10.
10. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, and Mazière B (1998). FDG accumulation and tumor biology. Nucl Med Biol 25, 317-322.
11. Macheda ML, Rogers S, and Best JD (2005). Molecular and cellular regulationof glucose transporter (Glut) proteins in cancer. J Cell Physiol 202, 654-662.
12. Smith TA (2000). Mammalian hexokinases and their abnormal expression incancer. Br J Biomed Sci 57, 170-178.
13. Abasolo I, Pujal J, Rabanal RM, Serafin A, Navarro P, Millán O, and Real FX (2009). FDG PET imaging of Ela1-myc mice reveals major biological differencesbetween pancreatic acinar and ductal tumours. Eur J Nucl Med Mol Imaging 36, 1156-1166.
14. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, and Jacks T (2004). Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860.
15. Hristov AC, Cope L, Di Cello F, Reyes MD, Singh M, Hillion JA, Belton A, Joseph B, Schuldenfrei A, Iacobuzio-Donahue CA, et al. (2010). HMGA1 correlateswith advanced tumor grade and decreased survival in pancreatic ductaladenocarcinoma. Mod Pathol 23, 98-104.
16. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, et al. (2006). Pathology of geneticallyengineered mouse models of pancreatic exocrine cancer: consensus reportand recommendations. Cancer Res 66, 95-106.
17. Hruban RH, Rustgi AK, Brentnall TA, Tempero MA, Wright CV, and Tuveson DA (2006). Pancreatic cancer in mice and man: the Penn Workshop 2004. Cancer Res 66, 14-17.
18. Fendrich V, Esni F, Garay MV, Feldmann G, Habbe N, Jensen JN, Dor Y, Stoffers D, Jensen J, Leach SD, et al. (2008). Hedgehog signaling regulates facultative progenitoractivity in regenerating exocrine pancreas. Gastroenterology 135, 621-631.
19. Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, and Malafa M (2008). PET/CT fusion scan enhances CT staging in patientswith pancreatic neoplasms. Ann Surg Oncol 15, 2465-2471.
20. Kalra MK, Blake MA, and Saini S (2004). Role of dual PET/CT scanning inabdominal malignancies. Cancer Imaging 4, 121-123.
21. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, and Pedrazzoli S (2007). 18-Fluorodeoxyglucose positron emission tomography enhances computedtomography diagnosis of malignant intraductal papillary mucinous neoplasmsof the pancreas. Ann Surg 246, 932-937.
22. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, Slater EP, Heverhagen JT, Gress TM, and Bartsch DK (2009). Familial pancreatic cancer-results of 5 years prospective screening of high risk individuals. Gut 58, 1410-1418.